Cadrenal Therapeutics (CVKD) News Today → On June 10, Nvidia makes its next big move (From Weiss Ratings) (Ad) Free CVKD Stock Alerts $0.47 +0.06 (+14.59%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 23, 2024 | prnewswire.comCadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cadrenal Therapeutics on Strong Clinical and Financial ProspectsMay 9, 2024 | prnewswire.comCadrenal Therapeutics Provides First Quarter 2024 Corporate UpdateApril 20, 2024 | finance.yahoo.comFavourable Signals For Cadrenal Therapeutics: Numerous Insiders Acquired StockApril 11, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | prnewswire.comCadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024April 11, 2024 | marketwatch.comCadrenal Therapeutics Gets FDA Orphan Drug Designation for TecarfarinApril 9, 2024 | markets.businessinsider.comCadrenal Therapeutics: FDA Grants Orphan Drug Designation For Tecarfarin; Stock JumpsApril 9, 2024 | bizjournals.comPonte Vedra-based Cadrenal Therapeutics receives second FDA orphan drug designationApril 9, 2024 | prnewswire.comCadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial HeartsMarch 14, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Cadrenal Therapeutics, Inc. (CVKD), Protara Therapeutics (TARA) and Spruce Biosciences (SPRB)March 11, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateMarch 11, 2024 | finance.yahoo.comCadrenal Therapeutics Provides Fourth Quarter 2023 Corporate UpdateFebruary 26, 2024 | prnewswire.comCadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) ConferenceFebruary 14, 2024 | morningstar.comCadrenal Therapeutics Inc CVKDFebruary 8, 2024 | finanznachrichten.deCadrenal Therapeutics, Inc.: Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialFebruary 8, 2024 | finance.yahoo.comCadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal TrialJanuary 31, 2024 | finance.yahoo.comCadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical ConditionsJanuary 30, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Cadrenal Therapeutics' (NASDAQ:CVKD) Cash Burn SituationJanuary 24, 2024 | finance.yahoo.comCadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024January 4, 2024 | finance.yahoo.comCadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare ConferenceDecember 19, 2023 | benzinga.comCadrenal Therapeutics Stock (NASDAQ:CVKD), Analyst Ratings, Price Targets, PredictionsDecember 11, 2023 | uk.finance.yahoo.comCadrenal Therapeutics, Inc. (CVKD)November 30, 2023 | finance.yahoo.comCadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023November 21, 2023 | msn.comHC Wainwright & Co. Initiates Coverage of Cadrenal Therapeutics (CVKD) with Buy RecommendationNovember 9, 2023 | msn.comCadrenal Therapeutics reports Q3 resultsNovember 9, 2023 | finance.yahoo.comCadrenal Therapeutics Provides Third Quarter 2023 Corporate UpdateOctober 9, 2023 | finance.yahoo.comCadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor ConferenceSeptember 5, 2023 | finance.yahoo.comCadrenal Therapeutics Highlights Additional Need for a New Vitamin K Antagonist (Tecarfarin) Following Updates from the Recent European Society of Cardiology CongressAugust 30, 2023 | finance.yahoo.comCadrenal Therapeutics Expands Evaluation of Tecarfarin for Patients with Antiphospholipid Syndrome (APS)August 28, 2023 | finance.yahoo.comCadrenal Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 18, 2023 | seekingalpha.comCVKD Cadrenal Therapeutics, Inc.August 10, 2023 | finance.yahoo.comCadrenal Therapeutics Provides Second Quarter 2023 Corporate UpdateAugust 1, 2023 | finance.yahoo.comCadrenal Therapeutics Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart DiseasesJuly 24, 2023 | finance.yahoo.comCadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of DirectorsJuly 14, 2023 | bizjournals.comPonte Vedra-based Cadrenal Therapeutics set to raise $7.5MJuly 12, 2023 | finance.yahoo.comCadrenal Therapeutics Announces $7.5 Million Private Placement Priced At-the-Market under Nasdaq RulesJuly 6, 2023 | finance.yahoo.comThe 3 Hottest IPOs to Buy Before They SoarJuly 4, 2023 | msn.comBest and worst performing healthcare IPOs of 2023, so farJune 1, 2023 | finance.yahoo.comCadrenal Therapeutics to Participate in the 2023 BIO International Convention in BostonMay 10, 2023 | finance.yahoo.comCadrenal Therapeutics Provides First Quarter 2023 Corporate UpdateMay 9, 2023 | finance.yahoo.comCadrenal Therapeutics to Participate in the Lytham Partners Spring 2023 Investor ConferenceMarch 30, 2023 | finance.yahoo.comCadrenal Therapeutics Provides Fiscal Year 2022 Corporate UpdateMarch 9, 2023 | finance.yahoo.comCadrenal Therapeutics Recognizes National Kidney Month with Goal to Advance Tecarfarin for Severely Underserved Patient PopulationFebruary 9, 2023 | bizjournals.comCadrenal celebrates IPO with bell ringing at NasdaqFebruary 8, 2023 | finance.yahoo.comCadrenal Therapeutics to Ring the NASDAQ Stock Market Closing Bell on February 8, 2023February 6, 2023 | finance.yahoo.comCadrenal Therapeutics to Participate in the 2023 BIO CEO & Investor ConferenceFebruary 1, 2023 | finance.yahoo.comCadrenal Therapeutics Announces Formation of Scientific Advisory BoardJanuary 28, 2023 | investing.comCadrenal Therapeutics Inc (CVKD)January 24, 2023 | finance.yahoo.comCadrenal Therapeutics (Nasdaq: CVKD) Announces Closing of Initial Public Offering Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address The only AI company to buy (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. CVKD Media Mentions By Week CVKD Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CVKD News Sentiment▼1.590.82▲Average Medical News Sentiment CVKD News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CVKD Articles This Week▼20▲CVKD Articles Average Week Get Cadrenal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CVKD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IPA News Today BOLT News Today NNVC News Today BIVI News Today RNXT News Today JAN News Today VIRX News Today ONCT News Today BCTX News Today APLM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CVKD) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaBiden Nomination CANCELED?The Freeport SocietyOn June 10, Nvidia makes its next big moveWeiss RatingsMAJOR BUY SIGNAL: Move Fast, Washington/Pelosi/Mill…AltimetryUnlock Explosive Gains with This Defense StockBehind the MarketsElon’s Revenge on BidenTradeSmithClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
